Table 3. Descriptive patient characteristics of advanced ALK-positive NSCLC patients receiving lorlatinib therapy and clinical outcome measures.
| Variables | Results (n=23) |
|---|---|
| Age (years) | 67.0 [30–84] |
| Sex | |
| Male | 7 (30.4) |
| Female | 16 (69.6) |
| Histology | |
| Adenocarcinoma | 22 (95.7) |
| Adenosquamous carcinoma | 1 (4.3) |
| ECOG PS | |
| 0–1 | 15 (65.2) |
| ≥2 | 8 (34.8) |
| Smoking history | |
| Never smoker | 11 (47.8) |
| Ex-smoker | 11 (47.8) |
| Smoker | 1 (4.3) |
| Brain metastasis | |
| Yes | 19 (82.6) |
| No | 4 (17.4) |
| First-line treatment | |
| TKI | 15 (65.2) |
| Chemotherapy | 8 (34.8) |
| Previous lines of ALK-TKI | 2.0 [1–3] |
| Prior ALK-inhibitors | |
| Crizotinib + 2nd generation ALK-TKI | 12 (52.2) |
| 2nd generation ALK-TKI | 11 (47.8) |
| Objective response rate | 13 (56.5) |
| DCR | 15 (65.2) |
| Complete response | 2 (8.7) |
| Partial response | 11 (47.8) |
| Stable disease | 2 (8.7) |
| Progressive disease | 5 (21.7) |
| Not evaluable | 3 (13.0) |
| Censored | 12 (52.2) |
| Follow-up (months) | 93.0 (72.9–113.1) |
| PFS (months) | 9.0 (0.77–17.2) |
| Post-lorlatinib survival (months) | 13.0 (0.0–29.7) |
| OS (months)† | 79.0 (26.6–131.4) |
Results are presented as median [range], n (%), or median (95% CI). †, median OS from advanced or metastatic NSCLC diagnosis. ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group; PS, performance status; TKI, tyrosine kinase inhibitor; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; CI, confidence interval.